Guardant Health, Inc.
GH
주식 순위
#1099
Guardant Health, Inc., established in Redwood City, California, in 2011, is a... Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
주가
$157.94
마지막 동기화: 2026-10-16
시가총액
$21.19B
변동 (1일)
-4.79%
변동 (1년)
141.28%
국가
US
거래 Guardant Health, Inc. (GH)
카테고리
Healthcare
Guardant Health, Inc. (GH)의 영업이익률
October 2026 기준 영업이익률 TTM: -39.75%
Guardant Health, Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 -39.75%입니다. 2023년 말 기준 영업이익률은 -100.14%였습니다.
Guardant Health, Inc.의 영업이익률 기록 (2016 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | -39.75% | -33.77% |
| 2024 | -60.02% | -40.06% |
| 2023 | -100.14% | -17.31% |
| 2022 | -121.10% | 10.09% |
| 2021 | -110.00% | 23.71% |
| 2020 | -88.92% | 131.44% |
| 2019 | -38.42% | -62.53% |
| 2018 | -102.54% | -33.29% |
| 2017 | -153.71% | -11.49% |
| 2016 | -173.66% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 17.97% | -100.45% |
US
|
|
| 20.42% | -100.51% |
US
|
|
| -10.70% | -99.73% |
US
|
|
| 0.00% | - |
CN
|
|
| 22.23% | -100.56% |
US
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.